芪杉胶囊联合NP化疗治疗晚期非小细胞肺癌患者临床研究
|
摘要
目的:研究芪杉胶囊联合长春瑞滨+顺铂(NP化疗)治疗晚期非小细胞肺癌患者的临床效果。方法:选取我院晚期非小细胞肺癌患者82例(2016年1月至2018年12月),简单随机化分为对照组(41例)、观察组(41例)。对照组给予NP化疗治疗,观察组给予芪杉胶囊+NP化疗治疗。治疗4个周期后,比较两组肿瘤病灶疗效、中医证候疗效、生活质量改善情况及不良反应发生情况。结果:观察组肿瘤病灶有效缓解率53.66%(22/41)、中医证候改善率85.37%(35/41)较对照组31.71%(13/41)、63.41%(26/41)高(P<0.05);观察组生活质量改善率90.24%(37/41)较对照组70.73%(29/41)高(P<0.05);观察组恶心呕吐、白细胞下降、肝功能损害、血小板下降发生率较对照组低,但差异无统计学意义(P>0.05)。结论:晚期非小细胞肺癌患者应用芪杉胶囊联合NP化疗治疗可显著提高肿瘤病灶疗效及中医证候疗效,还可明显改善生活质量,且不良反应发生率低,值得临床推广。
Objective: To study the clinical effect of Qishan capsule combined with NP chemotherapy(vinorelbine+cisplatin) in the treatment of advanced non-small cell lung cancer(NSCLC). Methods: 82 patients with advanced non-small cell lung cancer(from January 2016 to December2018) were randomly divided into control group(41 cases) and observation group(41 cases). The control group was treated with NP chemotherapy,while the observation group was treated with Qishan Capsule+NP chemotherapy. After 4 cycles of treatment, the curative effect of tumor focus,the curative effect of TCM syndromes, the improvement of quality of life and the occurrence of adverse reactions were compared between the two groups. Results: The effective remission rate of tumor focus was 53.66%(22/41) and the improvement rate of TCM syndromes was 85.37%(35/41),which was higher than 31.71%(13/41) and 63.41%(26/41) of the control group(P<0.05). The improvement rate of quality of life in the observation group was 90.24%(37/41), which was higher than 70.73%(29/41) in the control group(P<0.05). The occurrence of nausea and vomiting, leukopenia,liver dysfunction and thrombocytopenia in the observation group was lower than that of the control group, but there was no statistically significant difference(P>0.05). Conclusion: Qishan capsule combined with NP chemotherapy can significantly increase the curative effect of tumor focus and TCM syndromes in patients with advanced non-small cell lung cancer, remarkably improve the quality of life, and the incidence of adverse reactions is low, therefore, it is worthy of clinical promotion.
Objective: To study the clinical effect of Qishan capsule combined with NP chemotherapy(vinorelbine+cisplatin) in the treatment of advanced non-small cell lung cancer(NSCLC). Methods: 82 patients with advanced non-small cell lung cancer(from January 2016 to December2018) were randomly divided into control group(41 cases) and observation group(41 cases). The control group was treated with NP chemotherapy,while the observation group was treated with Qishan Capsule+NP chemotherapy. After 4 cycles of treatment, the curative effect of tumor focus,the curative effect of TCM syndromes, the improvement of quality of life and the occurrence of adverse reactions were compared between the two groups. Results: The effective remission rate of tumor focus was 53.66%(22/41) and the improvement rate of TCM syndromes was 85.37%(35/41),which was higher than 31.71%(13/41) and 63.41%(26/41) of the control group(P<0.05). The improvement rate of quality of life in the observation group was 90.24%(37/41), which was higher than 70.73%(29/41) in the control group(P<0.05). The occurrence of nausea and vomiting, leukopenia,liver dysfunction and thrombocytopenia in the observation group was lower than that of the control group, but there was no statistically significant difference(P>0.05). Conclusion: Qishan capsule combined with NP chemotherapy can significantly increase the curative effect of tumor focus and TCM syndromes in patients with advanced non-small cell lung cancer, remarkably improve the quality of life, and the incidence of adverse reactions is low, therefore, it is worthy of clinical promotion.
引文
[1]吴双,杨泽,张远净,等.局部晚期非小细胞肺癌诱导化疗后同期放化疗与同期放化疗疗效及安全性Meta分析[J].中华肿瘤防治杂志, 2017,24(1):55-61.
[2]檀叶青,邓书婧,陈文儒. EGFR突变在非小细胞肺癌患者治疗应用中的研究进展[J].标记免疫分析与临床, 2017, 24(10):1197-1200.
[3]熊德明,胡斌,徐耀凤,等.二甲双胍与同步放化疗联合应用于局部晚期非小细胞肺癌治疗中的临床效果[J].实用癌症杂志, 2018, 33(5):105-108.
[4]蒲嘉泽,陆鹏,潘英.华蟾素胶囊联合NP化疗对晚期非小细胞肺癌患者血清CYFRA21-1、NSE水平及免疫功能的影响[J].湖北中医药大学学报, 2017, 19(1):26-29.
[5]廖晓东,袁明,文祥飞,等.参芪扶正注射液联合NP方案在非小细胞肺癌术后辅助化疗中的临床应用[J].亚太传统医药, 2015, 11(19):87-89.
[6]王娜,朱晓燕,郭婷,等.中医辨证施治配合奈达铂联合多西他赛方案治疗晚期非小细胞肺癌的疗效[J].中国肿瘤临床与康复, 2015, 22(2):171-174.
[7]姜家康,迟文成,马宝柱,等.芪杉胶囊联合化疗治疗晚期非小细胞肺癌的临床疗效观察[J].中国中医基础医学杂志, 2017, 23(03):69-71.
[8]隋雨桐,迟文成,姜家康.芪杉胶囊对肺癌A549细胞PI3KAKt信号通路影响的研究[J].中医药学报, 2018, 46(04):26-31.
[2]檀叶青,邓书婧,陈文儒. EGFR突变在非小细胞肺癌患者治疗应用中的研究进展[J].标记免疫分析与临床, 2017, 24(10):1197-1200.
[3]熊德明,胡斌,徐耀凤,等.二甲双胍与同步放化疗联合应用于局部晚期非小细胞肺癌治疗中的临床效果[J].实用癌症杂志, 2018, 33(5):105-108.
[4]蒲嘉泽,陆鹏,潘英.华蟾素胶囊联合NP化疗对晚期非小细胞肺癌患者血清CYFRA21-1、NSE水平及免疫功能的影响[J].湖北中医药大学学报, 2017, 19(1):26-29.
[5]廖晓东,袁明,文祥飞,等.参芪扶正注射液联合NP方案在非小细胞肺癌术后辅助化疗中的临床应用[J].亚太传统医药, 2015, 11(19):87-89.
[6]王娜,朱晓燕,郭婷,等.中医辨证施治配合奈达铂联合多西他赛方案治疗晚期非小细胞肺癌的疗效[J].中国肿瘤临床与康复, 2015, 22(2):171-174.
[7]姜家康,迟文成,马宝柱,等.芪杉胶囊联合化疗治疗晚期非小细胞肺癌的临床疗效观察[J].中国中医基础医学杂志, 2017, 23(03):69-71.
[8]隋雨桐,迟文成,姜家康.芪杉胶囊对肺癌A549细胞PI3KAKt信号通路影响的研究[J].中医药学报, 2018, 46(04):26-31.